AFP Inhibitors
Common AFP Inhibitors include, but are not limited to Retinoic Acid, all trans CAS 302-79-4, Sorafenib CAS 284461-73-0, Sunitinib Malate CAS 341031-54-7, Brivanib alaninate CAS 649735-63-7 and ABT-869 CAS 796967-16-3.
AFP inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of Alpha-fetoprotein (AFP). AFP is a glycoprotein that is normally produced by the developing liver and yolk sac during fetal development. It serves important roles during embryogenesis, including nutrient transport and immune modulation. In adults, AFP production is typically low, but elevated levels may be observed in certain pathological conditions, such as liver cancer, germ cell tumors, and some gastrointestinal tumors.
AFP inhibitors work by specifically targeting the AFP protein, interfering with its functions during fetal development or in pathological states where AFP levels are elevated. By doing so, these inhibitors may impact the physiological processes regulated by AFP and contribute to a better understanding of its biological roles. Research into AFP and its inhibitors is ongoing to elucidate their mechanisms of action and explore their implications in various biological contexts. The study of AFP inhibitors represents an interesting area of research, contributing to our knowledge of AFP biology and its significance in different physiological and pathological conditions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Modulates AFP expression through retinoic acid receptors, leading to the differentiation of cells and inhibition of AFP-producing cancer cells. Used in research as a potential anti-cancer agent for AFP-positive tumors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multikinase inhibitor that indirectly impacts AFP expression by inhibiting signaling pathways, leading to decreased AFP production and antitumor effects in AFP-expressing cancers. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Multitargeted kinase inhibitor that indirectly influences AFP expression through VEGFR, PDGFR, and other pathways, leading to decreased AFP production and antiangiogenic effects in AFP-expressing cancers. | ||||||
Brivanib alaninate | 649735-63-7 | sc-480337 | 10 mg | $720.00 | ||
Dual inhibitor of VEGFR and FGFR, indirectly affecting AFP expression by inhibiting angiogenesis and tumor growth, leading to reduced AFP levels in AFP-expressing cancers. | ||||||
ABT-869 | 796967-16-3 | sc-359037 sc-359037A | 1 mg 5 mg | $126.00 $582.00 | ||
Multitargeted receptor tyrosine kinase inhibitor that indirectly influences AFP expression through VEGFR and PDGFR, leading to decreased AFP production and antiangiogenic effects in AFP-expressing cancers. | ||||||
Bemcentinib | 1037624-75-1 | sc-507363 | 10 mg | $900.00 | ||
A selective inhibitor of Axl kinase, which indirectly affects AFP expression through Axl signaling, leading to reduced AFP production and inhibition of cancer cell growth. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Multitargeted kinase inhibitor that indirectly influences AFP expression by inhibiting VEGFR, PDGFR, and FGFR signaling, leading to decreased AFP production and antiangiogenic effects in AFP-expressing cancers. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Agent that indirectly influences AFP expression by inhibiting DNA topoisomerase II, leading to cell cycle arrest and reduced AFP production in AFP-expressing cancers. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
Nucleoside analog that indirectly impacts AFP expression by inhibiting DNA synthesis, leading to reduced AFP production and antitumor effects in AFP-expressing cancers. | ||||||